Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19055
Title: | Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. | Austin Authors: | Bowyer, Samantha;Prithviraj, Prashanth;Lorigan, Paul;Larkin, James;McArthur, Grant;Atkinson, Victoria;Millward, Michael;Khou, Muoi;Diem, Stefan;Ramanujam, Sangeetha;Kong, Ben;Liniker, Elizabeth;Guminski, Alexander;Parente, Phillip;Andrews, Miles C;Parakh, Sagun ;Cebon, Jonathan S ;Long, Georgina V;Carlino, Matteo S;Klein, Oliver | Affiliation: | The Christie NHS Foundation Trust and University of Manchester, Manchester, UK Royal Marsden Hospital NHS Foundation Trust, London, UK Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia University of Sydney, Sydney, New South Wales, Australia Box Hill Hospital, Melbourne, Victoria, Australia Princess Alexandra Hospital, Greenslopes Private Hospital, Brisbane, Queensland, Australia Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia Melanoma Institute Australia, Sydney, New South Wales, Australia Department of Medical Oncology, Olivia Newton John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia School of Medicine and Pharmacology, University of Western Australia, Australia, Nedlands, Western Australia, Australia Rockingham General Hospital, Perth, Western Australia, Australia Westmead Hospital, Sydney, New South Wales, Australia |
Issue Date: | 11-Apr-2017 | Date: | 2017-03-21 | Publication information: | British Journal of Cancer 2017; 116(8): e15 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/19055 | DOI: | 10.1038/bjc.2017.59 | Journal: | British Journal of Cancer | PubMed URL: | 28324885 | Type: | Journal Article |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.